GSK stock last trades at GBp 1,860.00 on September 28, 2026
Published on 09/28/2026 at 23:16 | Editorial responsibility: Rafael MĂŒller, Editor-in-Chief AD HOC NEWS
GSK stock last traded at GBp 1,860.00 on the London Stock Exchange on September 28, 2026, according to the 15:39:49 UTC quote. The shares were up 0.49 percent from the previous sessionâs GBp 1,851.00.
Recent oncology transaction
On September 15, 2026, GSK said it had entered an agreement to acquire a trispecific T-cell engager from privately held Chimagen Biosciences. GSK plans to develop and commercialize the asset for multiple myeloma, with phase I trials expected to begin in 2027.
The agreement provides for an upfront payment and success-based development and commercial milestone payments. GSK said the deal has a total potential value of up to USD 750 million and remains subject to customary closing conditions.
Jideytro study results
In a September 14, 2026 release, GSK reported results from the phase I/II ARROS-1 trial of Jideytro in patients with advanced or metastatic ROS1-positive non-small cell lung cancer who had not previously received a tyrosine kinase inhibitor. Among 94 efficacy-evaluable patients, the objective response rate was 94.00 percent after a median follow-up of 15.2 months, while progression-free survival at 12 months was 90.00 percent.
